Differences clinical course zidovudine-treated asymptomatic HIV-infected men T-cell function intake T-cell numbers T-cell responsiveness prognostic markers progression HIV infection effect long-term zidovudine treatment immunological markers group asymptomatic men AIDS group untreated HIV-infected men AIDS control intake year start treatment T-cell numbers groups different time progressors low T-cell responsiveness non-progressors people T-cell responsiveness number T-cells months start zidovudine treatment T-cell numbers restoration T-cell responsiveness short duration results zidovudine treatment asymptomatic phase HIV infection sustained improvement T-cell function differences clinical course zidovudine-treated asymptomatics heterogeneity group respect T-cell functional capacity start treatment 